Optimal vaccine stockpile design for an eradicated disease: Application to polio

Vaccine

Volumn 28, Issue 26, 2010, Pages 4312-4327

  Duintjer Tebbens, Radboud J ^a,b   Pallansch, Mark A ^c   Alexander, James P ^c   Thompson, Kimberly M ^b  

^a DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b Kid Risk Inc   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Dynamics; Optimization; Polio eradication; Vaccine stockpile

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; DISEASE TRANSMISSION; DRUG STORAGE; DYNAMICS; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; POLIOMYELITIS; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS OPTIMIZATION; QUALITY CONTROL; SEROTYPE; VACCINATION;

DISEASE OUTBREAKS; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; MASS VACCINATION; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS VACCINES; RISK MANAGEMENT; WORLD HEALTH ORGANIZATION;

EID: 77952891960     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.001     Document Type: Article

References (44)

1. Normile D. Rinderpest. Driven to extinction. Science March (2008) 1606-1609
2. Duintjer Tebbens R.J., and Thompson K.M. Priority shifting and the dynamics of managing eradicable infectious disease. Management Science 55 April (4) (2009) 650-663
3. de Quadros C.A. Can measles be eradicated globally?. Bulletin of the World Health Organization 82 February (2) (2004) 134-138
4. Centers for Disease Control and Prevention. Recommendations of the International Task Force for Disease Eradication. Morbidity and Mortality Weekly Report December 31, 1993;42(RR-16).
5. Centers for Disease Control and Prevention. Global disease elimination and eradication as public health strategies. Morbidity and Mortality Weekly Report 1999;48(Suppl).
6. Milstien J. Global polio vaccine stockpile review and analysis (unpublished report) (2004), World Health Organization, Geneva
7. Lombard M., and Fuessel A.-E. Antigen and vaccine banks: technical requirements and the role of the European antigen bank in emergency foot and mouth disease vaccination. Scientific and Technical Review 26 1 (2007) 117-134
8. Arinaminpathy N., and McLean A.R. Antiviral treatment for the control of pandemic influenza: some logistical constraints. Journal of the Royal Society Interface 5 May (22) (2008) 545-553
9. Siddiqui M.R., and Edmunds W.J. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerging Infectious Diseases 14 February (2) (2008) 267-274
10. Gani R., Hughes H., Fleming D., Griffin T., Medlock J., and Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerging Infectious Diseases 11 September (9) (2005) 1355-1362
11. World Health Organization. Global Polio Eradication Initiative, Programme of Work 2009 and Financial Resource Requirements 2009-2013 as of May 2009. Geneva; 2009. Report No.: WHO/Polio/09.02.
12. Thompson K.M., Duintjer Tebbens R.J., and Pallansch M.A. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis 26 December (6) (2006) 1541-1556
13. Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Cáceres V.M., Sutter R.W., and Thompson K.M. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. American Journal of Epidemiology 162 August (4) (2005) 358-372
14. Stinnet A.A., and Paltiel D.A. Mathematical programming for the efficient allocation of health care resources. Journal of Health Economics 15 (1996) 641-653
15. Elbasha E.H., and Messonier M.L. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Economics 13 (2004) 21-35
16. Zaric G.S. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression. Health Economics 17 November (11) (2008) 1277-1294
17. Brandeau M.L., Zaric G.S., and Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. Journal of Health Economics 22 (2003) 575-598
18. Siciliani L. A note on the dynamic interaction between waiting times and waiting lists. Health Economics 17 (2008) 639-647
19. Siciliani L. A dynamic model of supply of elective surgery in the presence of waiting times and waiting lists. Journal of Health Economics 25 (2006) 891-907
20. Lovell K.C.A., Rodríguez-Álvarez A., and Wall A. The effects of stochastic demand and expense preference behaviour on public hospital costs and excess capacity. Health Economics 18 February (2) (2009) 227-235
21. Sterman J. Business dynamics: systems thinking and modeling for a complex world (2001), McGraw-Hill, Boston
22. Thompson K.M., and Duintjer Tebbens R.J. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis 26 December (6) (2006) 1423-1440
23. Thompson K.M., and Duintjer Tebbens R.J. Eradication versus control for poliomyelitis: an economic analysis. Lancet 369 April (9570) (2007) 1363-1371
24. Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Cáceres V.M., Jafari H., Cochi S.L., et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis 26 December (6) (2006) 1471-1505
25. World Health Organization. Report of an informal consultation on the identification and management of vaccine-derived polioviruses (VDPVs). Geneva, Switzerland: Vaccines & Biologicals Department; 2004.
26. Sangrujee N., Duintjer Tebbens R.J., Cáceres V.M., and Thompson K.M. Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine 5 December (4) (2003) 35
27. Thompson K.M., Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Sutter R.W., Aylward R.B., et al. The risks, costs, and benefits of global policies for managing polio after eradication. American Journal of Public Health 98 June (7) (2008) 1322-1330
28. Jenkins P.C., and Modlin J.F. Decision analysis in planning for a polio outbreak in the United States. Pediatrics 118 August (2) (2006) 611-618
29. Alexander L., Birkhead G., Guerra F., Helms C., Hinman A., Katz S., et al. Ensuring preparedness for potential poliomyelitis outbreaks: recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Archives of Pediatrics and Adolescent Medicine 158 December (12) (2004) 1106-1112
30. Joint Working Group of the National Vaccine Advisory Committee (NVAC) and Advisory Committee on Immunization Practices (ACIP). Needs and recommendations for the United States poliovirus vaccine stockpile. National Vaccine Program Office, U.S. Department of Health and Human Services; 2004.
31. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication. Exploring the role of antiviral drugs in the eradication of polio: workshop report (2006), National Academies Press, Washington, DC
32. World Health Organization. Standard operating procedures (SOPs) for the stockpile of monovalent oral poliovirus vaccines (mOPV) for the post-eradication/post-OPV era. Geneva, Switzerland; September 27, 2007.
33. World Health Organization. Global Polio Eradication Initiative: Strategic plan 2004-2008. Geneva; 2004.
34. Global Alliance for Vaccines and Immunization. Investment case for the polio stockpile, June 20, 2005, ; [accessed 07.01.06].
35. Dowdle W.R., van der Avoort H.G.A.M., de Gourville E.M., Delpeyroux F., Deshpande J.M., Hovi T., et al. Containment of polioviruses after eradication: characterizing risk to improve management. Risk Analysis 26 December (6) (2006) 1449-1469
36. World Health Organization. WHO global action plan to minimize poliovirus facility-associated risk in the post-eradication/post-OPV era. 3rd ed. (2007), World Health Organization, Geneva
37. Thompson K.M., and Duintjer Tebbens R.J. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. The Medscape Journal of Medicine 10 8 (2008) 190
38. Duintjer Tebbens R.J., Pallansch M.A., Kew O.M., Sutter R.W., Aylward R.B., Watkins M., et al. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis 28 August (4) (2008) 855-876
39. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 34 June (2) (2006) 151-154
40. Zhang J., Yu J.-J., Zhang R.-Z., Zhang X.-L., Zhou J., Wing J.S., et al. Costs of polio immunization days in China: implications for mass immunization campaign strategies. International Journal of Health Planning and Management 13 (1998) 5-25
41. Melnick J.L. Poliovirus and other enteroviruses. In: Evans A.S., and Kaslow R.A. (Eds). Viral infections of humans: epidemiology and control. 4th ed. (1997), Plenum Medical, New York 583-663
42. Sutter R.W., Kew O.M., and Cochi S.L. Poliovirus vaccine-live. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), W.B. Saunders Elsevier, Philadelphia 63-86
43. Halloran M.E., Longini I.M., Nizam A., and Yang Y. Containing bioterrorist smallpox. Science 298 November (5597) (2002) 1428-1432
44. Vanderbei R.J. Linear programming: foundations and extensions (2001), Springer-Verlag, New York, NY